$5.26
1.74% yesterday
Nasdaq, Sep 24, 10:00 pm CET
ISIN
US92764N1028
Symbol
VIR

Vir Biotechnology Inc Stock price

$5.26
+0.88 20.09% 1M
-1.94 26.94% 6M
-2.08 28.34% YTD
-2.28 30.24% 1Y
-13.00 71.19% 3Y
-27.02 83.71% 5Y
+1.57 42.55% 10Y
+1.57 42.55% 20Y
Nasdaq, Closing price Wed, Sep 24 2025
+0.09 1.74%

Key metrics

Basic
Market capitalization
$730.7m
Enterprise Value
$124.7m
Net debt
positive
Cash
$606.0m
Shares outstanding
138.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
38.5 | 62.9
EV/Sales
6.6 | 10.7
EV/FCF
negative
P/B
0.8
Financial Health
Equity Ratio
82.2%
Return on Equity
-45.4%
ROCE
-55.0%
ROIC
-106.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$19.0m | $11.6m
EBITDA
$-586.3m | $-492.3m
EBIT
$-597.8m | $-521.0m
Net Income
$-550.2m | $-461.0m
Free Cash Flow
$-466.4m
Growth (TTM | estimate)
Revenue
-75.9% | -84.3%
EBITDA
-12.6% | 10.8%
EBIT
-11.1% | 5.7%
Net Income
-13.9% | 11.7%
Free Cash Flow
-1.7%
Margin (TTM | estimate)
Gross
96.1%
EBITDA
-3,085.6% | -4,236.7%
EBIT
-3,146.5%
Net
-2,895.9% | -3,967.3%
Free Cash Flow
-2,454.6%
More
EPS
$-4.0
FCF per Share
$-3.4
Short interest
13.8%
Employees
408
Rev per Employee
$180.0k
Show more

Is Vir Biotechnology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Vir Biotechnology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Vir Biotechnology Inc forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Vir Biotechnology Inc forecast:

Buy
92%
Hold
8%

Financial data from Vir Biotechnology Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
19 19
76% 76%
100%
- Direct Costs 0.75 0.75
18% 18%
4%
18 18
77% 77%
96%
- Selling and Administrative Expenses 99 99
35% 35%
519%
- Research and Development Expense 517 517
11% 11%
2,723%
-586 -586
13% 13%
-3,086%
- Depreciation and Amortization 12 12
34% 34%
61%
EBIT (Operating Income) EBIT -598 -598
11% 11%
-3,146%
Net Profit -550 -550
14% 14%
-2,896%

In millions USD.

Don't miss a Thing! We will send you all news about Vir Biotechnology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vir Biotechnology Inc Stock News

Neutral
Seeking Alpha
9 days ago
Vir Biotechnology, Inc. (NASDAQ:VIR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:05 PM EDT Company Participants Marianne De Backer - CEO & Director Mark Eisner - Executive VP & Chief Medical Officer Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Good afternoon, everyone, and thanks ...
Neutral
Business Wire
about one month ago
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9 at 1:05 p.m. PT / 4:05 p.m. ET in New York, New York. A live webcast of the fireside chat will be made available under ...
Neutral
The Motley Fool
about 2 months ago
Vir Biotechnology (VIR -0.59%), a clinical-stage biotech focused on infectious diseases and immuno-oncology, reported results on August 6, 2025. The company announced a net loss per share of $(0.80) (GAAP).
More Vir Biotechnology Inc News

Company Profile

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Head office United States
CEO Marianne Backer
Employees 408
Founded 2016
Website www.vir.bio

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today